Abstract
Patients with common comorbidities, acute medication overuse (AMO), or difficult-to-treat migraine (DTTM) may have high healthcare resource utilization (HCRU) and costs. There are limited real-world data on use of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) targeting calcitonin gene-related peptide (CGRP), in these patients. This retrospective claims database study evaluated migraine-related HCRU and costs for patients with comorbidities, AMO, or DTTM initiating fremanezumab treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
